Literature DB >> 22887762

Expression analysis of a 17p terminal deletion, including YWHAE, but not PAFAH1B1, associated with normal brain structure on MRI in a young girl.

Keisuke Enomoto1, Yasuhiro Kishitani, Makiko Tominaga, Aki Ishikawa, Noritaka Furuya, Noriko Aida, Mitsuo Masuno, Ken-Ichiro Yamada, Kenji Kurosawa.   

Abstract

Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide (YWHAE), on chromosome 17p13.3, has been shown to play a crucial role in neuronal development. The deletion of YWHAE, but not platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 (PAFAH1B1), underlies a newly recognized neurodevelopmental disorder, characterized by significant growth retardation, developmental delay/intellectual disability (DD/ID), distinctive facial appearance, and brain abnormalities. Here, we report on a girl with a terminal deletion of 17p13.3, including YWHAE but not PAFAH1B1, showing normal brain structure on MRI. She had mild developmental delay, a distinctive facial appearance, and severe growth retardation despite normal growth hormone levels, which was improved by growth hormone therapy. Expression analysis of YWHAE and PAFAH1B1 yielded results consistent with array CGH and FISH results. These results indicate that the dosage effect of YWHAE varies from severe to very mild structural brain abnormalities, and suggest that the expression of YWHAE is associated with a complex mechanism of neuronal development.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22887762     DOI: 10.1002/ajmg.a.35542

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  1 in total

1.  17p13.3 Microdeletion: Insights on Genotype-Phenotype Correlation.

Authors:  Marshall I Barros Fontes; Ana P Dos Santos; Fábio Rossi Torres; Iscia Lopes-Cendes; Fernando Cendes; Simone Appenzeller; Tânia Kawasaki de Araujo; Isabella Lopes Monlleó; Vera L Gil-da-Silva-Lopes
Journal:  Mol Syndromol       Date:  2016-11-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.